Carisma Therapeutics Inc. - Common Stock, $0.001 par value per share (CARM) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2023 to Q4 2025

Type / Class
Equity / Common Stock, $0.001 par value per share
Symbol
CARM on OTC
Shares outstanding
41,966,083
Price per share
$0.04
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
3,076,046
Total reported value
$842,564
% of total 13F portfolios
0%
Share change
-906,393
Value change
-$350,306
Number of holders
31
Price from insider filings
$0.04
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Carisma Therapeutics Inc. - Common Stock, $0.001 par value per share (CARM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
AbbVie Biotechnology Ltd 4.4% $408,292 1,855,871 AbbVie Biotechnology Ltd. 31 Mar 2025

As of 30 Sep 2025, 31 institutional investors reported holding 3,076,046 shares of Carisma Therapeutics Inc. - Common Stock, $0.001 par value per share (CARM). This represents 7.3% of the company’s total 41,966,083 outstanding shares.

Institutional Holders of Carisma Therapeutics Inc. - Common Stock, $0.001 par value per share (CARM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 985 $36 -$32 $0.04 2
2025 Q3 3,076,046 $842,564 -$350,306 $0.27 31
2025 Q2 3,982,439 $1,556,940 -$560,771 $0.39 34
2025 Q1 5,575,722 $1,728,189 -$36,721 $0.31 36
2024 Q4 5,622,649 $2,353,797 -$593,771 $0.42 40
2024 Q3 5,205,020 $5,110,606 -$959,217 $0.98 37
2024 Q2 6,107,903 $9,284,001 -$4,059,329 $1.52 50
2024 Q1 8,506,493 $19,308,656 -$1,165,944 $2.27 49
2023 Q4 8,999,825 $26,370,118 -$1,294,700 $2.93 49
2023 Q3 9,367,840 $39,626,274 -$892,640 $4.23 56
2023 Q2 9,581,087 $84,025,633 +$38,213,873 $8.77 52
2023 Q1 5,567,108 $17,259,637 +$17,258,816 $3.10 34